Eski E, Babakurban S, Yılmaz S, Yılmazer C, Erkan AN, Çaylaklı F, Yılmaz İ, et al.
The journal of international advanced otology. Date of publication 2020 Aug 1;volume 16(2):263-265.
1. J Int Adv Otol. 2020 Aug;16(2):263-265. doi: 10.5152/iao.2020.6634.
Comparing the Efficiencies of Hyperbaric Oxygen Therapy and Intratympanic
Steroid Treatment for Sudden Hearing Loss.
Eski E(1), Babakurban S(2), Yılmaz S(3), Yılmazer C(3), Erkan AN(3), Çaylaklı
F(3), Yılmaz İ(3).
Author information:
(1)Department of Otolaryngology, Baskent University, İzmir, Turkey.
(2)Department of Otolaryngology, Baskent University, Ankara, Turkey.
(3)Department of Otolaryngology, Baskent University, Adana, Turkey.
OBJECTIVES: To compare the efficiencies of hyperbaric oxygen therapy (HBOT) and
intratympanic steroid (ITS)treatment for idiopathic sudden sensorineural
hearingloss (ISSHL).
MATERIALS AND METHODS: A total of 136 patients who were treated for ISSHL were
reviewed fromthemedical records. All of the patients were given systemic steroid
therapy (SST). Among them,33patients received HBOT and 36 patients received ITS
treatment following SST. The starting time to treatment, risk factors, hearing
level, hearing gain (HG), and recovery rate were evaluated from
retrospectiverecords.
RESULTS: No substantial change in HG was observed for either the HBOT or ITS
treatment cohort (p>0.05). But the time to recovery was higher in the ITS
treatment cohort (40%) than in theHBOT cohort (17%). The starting time to ITS
treatment was 4 days (range: 1-30) and that to HBOT was 8 days (range:3-30).
There was a significant difference in the starting time to treatment
(Mann-Whitney U-test, p=0.043). Also, hearing loss in the HBOT group was
significantly higher than in the ITS treatment group. A significant difference
was observed before and after ITS treatment (p<0.05).
CONCLUSION: In patients compared with late-onset treatment, ITS may be more
effective than HBO after SST failure. It can be used as salvage therapy in
patients with ISSHL who are unresponsive to a primary systemic steroid. We
observed that HBOT didnot improve results when it was started late. Therefore,
more studies that include both ITS treatment and HBOTas anearly treatment option
are needed.
DOI: 10.5152/iao.2020.6634
PMCID: PMC7419095
PMID: 32784167 [Indexed for MEDLINE]
Conflict of interest statement: Conflict of Interest: The authors declare that
they have no conflict of interest.
